Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-‘1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

Initiation of study marks an important milestone in advancing Neurocrine’s obesity portfolio and investigational metabolic disease pipeline